These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Characteristics of long-term alprazolam users in the community. Romach MK; Somer GR; Sobell LC; Sobell MB; Kaplan HL; Sellers EM J Clin Psychopharmacol; 1992 Oct; 12(5):316-21. PubMed ID: 1479048 [TBL] [Abstract][Full Text] [Related]
4. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. Klein E J Clin Psychiatry; 2002; 63 Suppl 14():27-33. PubMed ID: 12562116 [TBL] [Abstract][Full Text] [Related]
7. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs. Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197 [TBL] [Abstract][Full Text] [Related]
8. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Spiegel DA; Bruce TJ; Gregg SF; Nuzzarello A Am J Psychiatry; 1994 Jun; 151(6):876-81. PubMed ID: 8184997 [TBL] [Abstract][Full Text] [Related]
9. The long-term treatment of panic disorder. Davidson JR J Clin Psychiatry; 1998; 59 Suppl 8():17-21; discussion 22-3. PubMed ID: 9707158 [TBL] [Abstract][Full Text] [Related]
10. Cognitive-behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. Bruce TJ; Spiegel DA; Hegel MT J Consult Clin Psychol; 1999 Feb; 67(1):151-6. PubMed ID: 10028220 [TBL] [Abstract][Full Text] [Related]
11. Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder. Bruce TJ; Spiegel DA; Gregg SF; Nuzzarello A Am J Psychiatry; 1995 Aug; 152(8):1156-60. PubMed ID: 7625463 [TBL] [Abstract][Full Text] [Related]
13. Use of benzodiazepines in panic disorder. Davidson JR J Clin Psychiatry; 1997; 58 Suppl 2():26-8; discussion 29-31. PubMed ID: 9078991 [TBL] [Abstract][Full Text] [Related]
14. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. Chouinard G J Clin Psychiatry; 2004; 65 Suppl 5():7-12. PubMed ID: 15078112 [TBL] [Abstract][Full Text] [Related]
15. Continuation treatment of panic disorder with high-potency benzodiazepines. Davidson JR J Clin Psychiatry; 1990 Dec; 51 Suppl A():31-7. PubMed ID: 2258375 [TBL] [Abstract][Full Text] [Related]
16. Efficacy studies of alprazolam in panic disorder. Spiegel DA Psychopharmacol Bull; 1998; 34(2):191-5. PubMed ID: 9640999 [TBL] [Abstract][Full Text] [Related]
17. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. Jonas JM; Cohon MS J Clin Psychiatry; 1993 Oct; 54 Suppl():25-45; discussion 46-8. PubMed ID: 8262888 [TBL] [Abstract][Full Text] [Related]
18. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Pecknold JC; Swinson RP; Kuch K; Lewis CP Arch Gen Psychiatry; 1988 May; 45(5):429-36. PubMed ID: 3282479 [TBL] [Abstract][Full Text] [Related]
19. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Klein E; Colin V; Stolk J; Lenox RH Am J Psychiatry; 1994 Dec; 151(12):1760-6. PubMed ID: 7977882 [TBL] [Abstract][Full Text] [Related]
20. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Otto MW; Pollack MH; Sachs GS; Reiter SR; Meltzer-Brody S; Rosenbaum JF Am J Psychiatry; 1993 Oct; 150(10):1485-90. PubMed ID: 8379551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]